What Happened?
, -based Sage Therapeutics Promoted Adam Stein as Director, Corporate Counsel
Date of management change: April 06, 2024
, -based Sage Therapeutics Promoted Adam Stein as Director, Corporate Counsel
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Adam Stein is Director, Corporate Counsel at Sage Therapeutics. Previously, Adam held various senior legal leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: King Lea, Stevens Sandra, Kauth Amanda, Fisanich Frank, Jones Pam, Gray-Kemp Felice, Roufogalis Jason, Conrad Dan, Tymeson Chris, Kravik Susan, Pittman Tabor
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.